Stock 4519CHUGAI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Chugai Pharmaceutical Co., Ltd. Share Price

Equities

4519

JP3519400000

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 07:30:00 20/06/2025 BST 		5-day change 1st Jan Change
7,189.00 JPY -0.28% Intraday chart for Chugai Pharmaceutical Co., Ltd. -3.59% +2.71%
06-13 Chugai Pharmaceutical Co., Ltd. - Shareholder/Analyst Call
05-19 Rani Therapeutics Holdings, Inc. Announces Research Agreement with Chugai Pharmaceutical Co., Ltd CI

Valuation: Chugai Pharmaceutical Co., Ltd.

Capitalization 11,830B 81.11B 70.36B 66.27B 60.22B 111B 7,025B 126B 785B 300B 3,218B 304B 298B P/E ratio 2025 *
27.1x
P/E ratio 2026 * 25.5x
Enterprise value 11,064B 75.86B 65.8B 61.98B 56.32B 104B 6,570B 117B 734B 281B 3,010B 285B 279B EV / Sales 2025 *
9.05x
EV / Sales 2026 * 8.65x
Free-Float
38.09%
Yield 2025 *
3.33%
Yield 2026 * 1.64%
More valuation ratios * Estimated data

Chart: Chugai Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news: Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd. - Shareholder/Analyst Call 06-13
Rani Therapeutics Holdings, Inc. Announces Research Agreement with Chugai Pharmaceutical Co., Ltd 05-19 CI
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices 05-12 DJ
Japan's Nikkei ends higher on US-China trade deal hopes 05-12 RE
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs 05-12 DJ
Chugai Pharmaceutical Co., Ltd., Q1 2025 Earnings Call, Apr 24, 2025 04-24
Jefferies Adjusts Chugai Pharmaceutical's Price Target to 8,400 Yen From 7,700 Yen, Keeps at Hold 04-24 MT
Roche: U.S. investment plans will not be at expense of other parts of world 04-24 RE
Chugai Pharmaceutical Achieves Positive Phase 3 Results for Orforglipron in Type 2 Diabetes 04-21 MT
Japan's Nikkei notches best week in 3 months on trade deal hopes 04-18 RE
Japan's Nikkei heads for best week in 3 months on trade deal hopes 04-18 RE
Chugai Pharmaceutical to Dispose of 79,800 Treasury Shares 04-01 MT
Chugai Pharma Weighs Lowering Investment Unit to Boost Liquidity 03-27 MT
More news

Last Transcript: Chugai Pharmaceutical Co., Ltd.

Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. - Shareholder/Analyst Call
06-13
More transcripts

Analysts' recommendations: Chugai Pharmaceutical Co., Ltd.

Jefferies Adjusts Chugai Pharmaceutical's Price Target to 8,400 Yen From 7,700 Yen, Keeps at Hold 04-24 MT
Jefferies Downgrades Chugai Pharmaceutical to Hold From Buy, Adjusts Price Target to 7,700 Yen From 7,100 Yen 30/10/24 MT
Jefferies Adjusts Chugai Pharmaceutical's Price Target to 7,100 Yen From 7,000 Yen, Keeps at Buy 26/07/24 MT
Jefferies Adjusts Chugai’s Price Target to 7,000 Yen From 6,200 Yen, Keeps at Buy 04/03/24 MT
Jefferies Adjusts Chugai Pharmaceutical’s Price Target to 6,200 Yen From 5,400 Yen, Keeps at Buy 14/12/23 MT
More recommendations

Press Releases: Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical : Roche Announces New Safety Information of Elevidys for Non-Ambulatory Duchenne Muscular Dystrophy 06-16 PU
Chugai Pharmaceutical : Galderma’s Announcement Regarding NEMLUVIO (New Long Term Data Presentation in Atopic Dermatitis) 06-11 PU
Chugai Pharmaceutical : Annual Report (eAR2024 12 single) 05-30 PU
Chugai Pharmaceutical : Verastem Oncology’s Announcement Regarding AVMAPKI (Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma) 05-22 PU
Chugai Pharmaceutical Co., Ltd. - Positive Results from Phase III TALENTACE Study of Tecentriq and Avastin for Unresectable Hepatocellular Carcinoma 05-22 AQ
More press releases

News in other languages: Chugai Pharmaceutical Co., Ltd.

MÄRKTE ASIEN/Uneinheitlich - Börse in Indien nach Zinssenkung fester 06-06
MÄRKTE ASIEN/Aktien widerstandsfähig nach mauer US-Vorlage 06-06
MÄRKTE ASIEN/Spekulation auf US-chinesische Einigung sorgt für Kauflaune 05-12
MÄRKTE ASIEN/Freundlich - Hoffnung auf US-chinesische Annäherung lebt 05-12
Make America Gamble Again 04-24
More news

Quotes and Performance

1 day-0.28%
1 week-3.59%
Current month-5.20%
1 month-5.00%
3 months+6.73%
6 months+8.11%
Current year+2.71%
More quotes

Course Extremes

1 week 7,184
Extreme 7184
 7,534
1 month 7,184
Extreme 7184
 7,778
Current year 6,232
Extreme 6232
 8,655
1 year 5,191
Extreme 5191
 8,655
3 years 3,191
Extreme 3191
 8,655
5 years 3,191
Extreme 3191
 8,655
10 years 1,003.33
Extreme 1003.3333
 8,655
More quotes

Managers and Directors: Chugai Pharmaceutical Co., Ltd.

Manager TitleAgeSince
Osamu Okuda CEO
 Chief Executive Officer 62 31/12/2020
Iwaaki Taniguchi DFI
 Director of Finance/CFO - 27/03/2024
Junichi Nezu CTO
 Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Motoo Ueno BRD
 Director/Board Member 67 28/02/1993
Masayuki Oku BRD
 Director/Board Member 80 28/02/2015
Yoichiro Ichimaru BRD
 Director/Board Member 76 28/02/2017
More insiders

ETFs: Chugai Pharmaceutical Co., Ltd.

Name Weight AuM 1st Jan change
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY ETF Nomura NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY
6.57% 28 M€ -7.66% -
NOMURA NEXT FUNDS MSCI JAPAN EMPOWERING WOMEN SELECT INDEX ETF - JPY ETF Nomura NEXT FUNDS MSCI Japan Empowering Women Select Index ETF - JPY
1.87% 60 M€ -0.50% -
DAIWA ETF MSCI JAPAN EMPOWERING WOMEN INDEX ETF - JPY ETF Daiwa ETF MSCI Japan Empowering Women Index ETF - JPY
1.59% 2 M€ -1.29% -
NOMURA NIKKEI 225 EXCHANGE TRADED FUND ETF - JPY ETF Nomura Nikkei 225 Exchange Traded Fund ETF - JPY
1.53% 60,944 M€ -2.92% -
More ETFs: Chugai Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
CHUGAI PHARMACEUTICAL CO., LTD. Stock Chugai Pharmaceutical Co., Ltd.
-0.28%-3.59%+39.81%+116.93% 81.4B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-2.84%-6.91%-13.91%+162.20% 705B
JOHNSON & JOHNSON Stock Johnson & Johnson
-0.62%-4.65%+1.36%-11.61% 363B
NOVO NORDISK A/S Stock Novo Nordisk A/S
-2.58%-7.83%-52.12%+25.00% 333B
ABBVIE INC. Stock AbbVie Inc.
-0.10%-3.02%+7.65%+34.00% 328B
ROCHE HOLDING AG Stock Roche Holding AG
-0.27%-3.86%+3.72%-14.84% 255B
NOVARTIS AG Stock Novartis AG
-0.34%-2.34%+0.59%+19.15% 228B
ASTRAZENECA PLC Stock AstraZeneca PLC
-1.52%-5.41%-16.18%+3.36% 220B
MERCK & CO., INC. Stock Merck & Co., Inc.
-0.29%-3.24%-39.03%-6.57% 199B
AMGEN INC. Stock Amgen Inc.
-0.10%-2.00%-6.63%+23.27% 156B
Average -0.28%-4.15%-7.47%+35.09% 286.64B
Weighted average by Cap. -0.18%-4.62%-11.23%+49.79%
See all sector performances

Financials

2025 *2026 *
Net sales 1,223B 8.38B 7.27B 6.85B 6.22B 11.52B 726B 12.98B 81.13B 31.05B 333B 31.46B 30.79B 1,255B 8.6B 7.46B 7.03B 6.39B 11.82B 745B 13.31B 83.25B 31.86B 341B 32.28B 31.6B
Net income 436B 2.99B 2.59B 2.44B 2.22B 4.1B 259B 4.63B 28.92B 11.07B 119B 11.21B 10.98B 454B 3.11B 2.7B 2.54B 2.31B 4.27B 270B 4.82B 30.11B 11.52B 123B 11.68B 11.43B
Net Debt -766B -5.25B -4.56B -4.29B -3.9B -7.21B -455B -8.13B -50.82B -19.45B -208B -19.71B -19.29B -980B -6.72B -5.83B -5.49B -4.99B -9.23B -582B -10.4B -65.01B -24.88B -267B -25.21B -24.68B
More financial data * Estimated data

Company Profile

Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Employees
5,026
Sector
Pharmaceuticals
Calendar
06-26 - Détachement de for dividende intermédiaire
More about the company

Quotes

Date Price Change Volume
20/06/25 7,189.00 ¥ -0.28% 2,599,900
19/06/25 7,209.00 ¥ -1.25% 1,346,200
18/06/25 7,300.00 ¥ -1.14% 2,087,300
17/06/25 7,384.00 ¥ -1.05% 1,440,300
16/06/25 7,462.00 ¥ +0.07% 1,453,900

Delayed Quote Japan Exchange, June 20, 2025 at 07:30 am

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
7,189.00JPY
Average target price
8,303.57JPY
Spread / Average Target
+15.50%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 4519 Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition